GERN 241220 2.50P (GERN241220P2500) Stock Options, News & Quotes

US OptionsDetailed Quotes

GERN241220P2500

Watchlist

0.02
0.000.00%

15min DelayClose Nov 29 13:00 ET

0.00High0.00Low

Intraday

5D
Daily

News

Barclays Initiates Geron(GERN.US) With Buy Rating, Announces Target Price $9
Moomoo NewsNov 30 13:32 ET · Ratings
Geron Q4 Revenue Estimate Raised Above Consensus at Barclays
TipRanksNov 30 12:40 ET
Geron to Participate in the 7th Annual Evercore ISI HealthCONx Conference
BusinesswireNov 27 09:00 ET
Express News | Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
ReutersNov 21 16:30 ET
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BusinesswireNov 21 16:30 ET
Express News | Geron Corporation Announces Appointment of Joseph Eid, M.d. as Executive Vice President, Research and Development
ReutersNov 11 16:30 ET

Comments

Tonyco

Nov 17 17:09

$Geron (GERN.US)$
Almost low enough

Trytosaveabit

Nov 7 06:27

A bit more

$Geron (GERN.US)$ Reuters· 2 mins ago
Geron Corp - Receives $250 Million at Closing, $125 Million in Debt Available

Trytosaveabit

Nov 7 06:13

News

$Geron (GERN.US)$ Reuters· 1 mins ago
Royalty Pharma to Acquire Royalty Interest in Geron’s Rytelo for $125 Million

Trytosaveabit

Nov 7 06:05

Some

$Geron (GERN.US)$ Geron Corporation Reports Third Quarter 2024 Financial Results and Recent Business Highlights
Achieved $28.2 million in RYTELO(TM) (imetelstat) net product revenue in first full quarter of sales
Received $250 million in gross proceeds from synthetic royalty and debt financings with Royalty Pharma and Pharmakon Advisors, with access to an additional $125 million in debt

Trytosaveabit

Nov 7 06:05

$Geron (GERN.US)$ 🤔